International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2014

Related Enduring Materials

Enduring Materials

Session 1: Pharmacokinetics & Pharmacodynamics of Approved TB drugs in Special Populations -

Clinical Pharmacology Issues for Pediatric TB

Sharon Nachman, MD

SUNY Health Science Center Stony Brook / IMPAACT Network, United States

Slideset

Pharmacokinetics of rifampicin, isoniazid and pyrazinamide in children on 2010 WHO/IUATLD guideline doses

H. McIlleron

#01

Slideset

A simultaneous population pharmacokinetic analysis in Malawian adults and children of rifampicin

A. Schipani

#02

Slideset

Pharmacokinetics of rifampin among pregnant women with tuberculosis and HIV co-infection

K. Dooley

#03

Slideset

Session 2: Pharmacokinetics & Pharmacodynamics of New and Redeveloped TB Drugs -

The Critical Path to TB Drug Regimens: Advancing through a Multidisciplinary, Multipartner Approach

Klaus Romero, MD, MS

USC School of Pharmacy, USA

Slideset

Drug-drug interactions between bedaquiline and the antiretrovirals nevirapine and lopinavir/ritonavir in patients

M. Pandie

#04

Slideset

High dose rifampicin: a phase II trial comparing 10, 15 and 20 mg/kg rifampicin for two months

R. Aarnoutse

#05

Slideset

Population pharmacokinetics and bacterial dynamics of sutezolid in patients with active tuberculosis

K.B. Larson

#06

Slideset

The inhibitory potential of TB drugs on ATP-binding cassette transporters MRP1- 5, P-gp, BCRP and BSEP

L. Te Brake

#07

Slideset

Session 3: Pharmacokinetic & Pharmacodynamic Modeling -

Pharmacological Knowledge Gaps in the Treatment of TB Meningitis

Guy Thwaites, MA, MBBS, PhD, FRCP, FRCPath, FMedSci

Oxford University, UK

Slideset

A quantitative and systems pharmacology approach to dose optimization in experimental tuberculosis: opportunities and experimental data needs

M. Lyons

Slideset

A semi mechanistic pharmacokinetic-pharmacodynamic template model for studying antitubercular drug effects in vitro

O. Clewe

Slideset

Pharmacokinetics of levofloxacin in M(X)DR tuberculosis patients

N. Van’t Boveneind- Vrubleuskaya

#10

Slideset

Session 4: Drug Development and Optimization: Approaches & Tools -

Inhaled Therapy for TB

Edward Nardell, MD

Harvard Medical School, USA

Slideset

Intra cavitary penetration of levofloxacin among patients with multidrug-resistant tuberculosis

R. Kempker

#11

Slideset

Anti-Tuberculosis Activity of Pyrazinamide Varies by Lesion Type in C3heb/Fej Mice

Lanoix, J.-P

#12

Slideset

Real-time and non-invasive, multi-compartment pharmacokinetics of 11c-rifampin in mycobacterium tuberculosis infected mice using dynamic positron emission tomography

V.P. DeMarco

#13

Slideset

Computational pharmacology of rifampin in mice: an application to dose optimization with conflicting objectives in tuberculosis treatment

M. Lyons

#14

Slideset

Overview

Welcome

Dear colleagues,

The 7th edition of the International Workshop on Pharmacology of Tuberculosis Drugs, which has been held on 5 September 2014 in Washington DC, USA, preceding the ICAAC 2014, has been a tremendous success.

Excellent presentations by the invited speakers and the poster presentors have created a very interesting program.

We would like to thank all attendees for their participation and input and we would like to express our appreciation to everyone who took the time to fill in the evaluation form at the end of the conference. Thank you for your feedback and suggestions!

Kind regards,

The Organizing Committee

Rob Aarnoutse, PharmD, PhD

Radboud University Medical Center, Netherlands

Geraint Rhys Davies, BM, PhD, FRCP, DTM&H

Liverpool University Hospitals Foundation Trust / University of Liverpool, United Kingdom

Helen McIlleron, MBChB, PhD

University of Cape Town, South Africa

Eric Nuermberger, MD

Johns Hopkins University, United States

Charles Peloquin, PharmD

University of Florida, United States

Khisi Mdluli, PhD

TB Alliance, USA

General Information

Meeting Objectives

- To gather experts involved in the pharmacology of TB drugs from different disciplines in an interactive workshop setting
- To provide a platform for presentation and discussion of the latest scientific developments in the field.
- To map all current studies and results related to available and new TB drugs
- To help translate new in vitro and in vivo pharmacological data into new drug treatment combinations for TB

Unique Features

Our workshop involves a strong community of clinical pharmacologists and other healthcare professionals working in the TB-field. Also, the workshop provides an independent scientific platform to discuss controversial topics and views.

Practical Information

Disclaimer

This workshop is intended for educational purposes only and aims to offer participants the opportunity to share information. The organizing secretariat of this workshop, Expert Medical Events, cannot accept any liability for the scientific content of the sessions or for any claims which may result from the use of information or publications from this workshop. Expert Medical Events disclaims all liability for injuries or losses of whatever nature incurred by individuals attending the workshop.

Liability and Insurance

By registering for the conference participants agree that the organizers do not accept responsibility for medical, travel, or personal insurance. Participants are advised to take out their own insurance policies.

Photograph, Audio and Video Recording

Photographs as well as audio and video recordings are not permitted during official meeting sessions. Only the official medical writer appointed by the organization may make recordings. All presentations will be posted on the workshop website as soon as possible following the meeting, provided the speaker has given us permission to use their presentation online.